Dr. Jack Regan, CEO of LexaGene, shares his work identifying the future biothreats human and veterinary populations may face.
GenomeWeb picked up our announcement and reports on LexaGene’s cooperative research agreement with the US Army.
In the latest issue of the Pathologist, Dr. Jack Regan discusses the strategic priorities and technologies that could prevent the next global pandemic:
Benzinga describes how LexaGene has built MiQLab, a new molecular diagnostics analyzer that can do in-clinic veterinary diagnostic testing at the point-of-care.
LexaGene covered in BioWorld on the MiQLab’s ability to detect new variants of pathogens at point-of-care.